The FDA and Sanofi-Aventis, the makers of the arterial fibrillation drug Multaq, have issued a warning for potential liver damage in patients taking the medication.
Patients taking Multaq are should immediately report any symptoms suggestive of liver dysfunction to their physician. Symptoms of liver dysfunction include:
- Loss of appetite
- Nausea
- Vomiting
- Unusual fatigue
- Right upper stomach area pain
- Yellowing of the skin/eyes
- Unusual darkening of urine
- Itching
Any adverse reaction to Multaq or any other medication should reported to the FDA through the agency’s Medwatch program. For more information see the FDA’s Drug Safety Communication here.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.